Aspen Pharmacare gets USD 30 million grant to make vaccines

Published On 2022-12-13 08:15 GMT   |   Update On 2022-12-13 08:15 GMT

Johannesburg: Aspen Pharmacare has wrapped up pacts to secure funding of $30 million from the Gates Foundation and the Coalition for Epidemic Preparedness Innovations to help make affordable vaccines for Africa, the company said on Monday.

In August, Aspen announced a deal with the Serum Institute of India to make and sell four Aspen-branded vaccines for Africa, as it looks to use its near-idle COVID-19 vaccine production lines in South Africa.

It had been negotiating with the two organizations for grant funding.

"The new funding from CEPI and the Gates Foundation will support a ten-year agreement between Aspen and Serum Institute that aims to expand the supply and sourcing of affordable vaccines manufactured in Africa," the company said.

Each of the two will contribute $15 million.

The Serum Institute agreement provides for Aspen to make and distribute pneumococcal, rotavirus, polyvalent meningococcal, and hexavalent vaccines commonly administered in Africa.

Advertisement

It gives Aspen certainty on volumes, which will eventually more than cover an expected fall in revenue from its COVID vaccine contract with Johnson & Johnson, Chief Executive Stephen Saad said in August.

On Monday, Aspen said the funding, in addition to supporting the "technology transfer activities" set to begin early in 2023, will help sustain its regional vaccine making capacity against future outbreaks.

Read also: Serum Institute Adar Poonawalla makes clarion call for global certification of vaccines

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News